| DC Field | Value | Language |
|---|
| dc.contributor.author | Kostina, D. A. | - |
| dc.contributor.author | Pokrovskaya, T. G. | - |
| dc.contributor.author | Beskhmelnitsyna, E. A. | - |
| dc.date.accessioned | 2022-05-04T11:39:02Z | - |
| dc.date.available | 2022-05-04T11:39:02Z | - |
| dc.date.issued | 2017 | - |
| dc.identifier.citation | Kostina, D.A. Interleukin-6 is a potential target for a correction of endothelial dysfunction associated with low-grade systemic inflammation / D.A. Kostina, T.G. Pokrovskaya, E.A. Beskhmelnitsyna // Research result. Pharmacology and clinical pharmacology. - 2017. - Vol. 3, № 3.- P. 89-96. - Doi: 10.18413/2313-8971-2017-3-3-89-96. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46578 | - |
| dc.description.abstract | One of pathogenetic links of development of endothelial dysfunction, as an early marker of cardiovascular disease and comorbidity, is a low-grade systemic inflammation. In this regard, correction of cytokines imbalance is one of the possible ways of prevention and treatment of major chronic noninfectious diseases. To study the endothelium protective effects of anti-IL-6 receptor monoclonal antibodies tocilizumab in experimental preclinical studies in a model of endothelial dysfunction associated with the low-grade systemic inflammation | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | internal illnesses | ru |
| dc.subject | endothelial dysfunction | ru |
| dc.subject | low-grade systemic inflammation | ru |
| dc.subject | interleukin-6 | ru |
| dc.subject | tocilizumab | ru |
| dc.title | Interleukin-6 is a potential target for a correction of endothelial dysfunction associated with low-grade systemic inflammation | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 3, № 3
|
